Bristol Myers Squibb Company $BMY Shares Sold by Hamilton Wealth LLC

Hamilton Wealth LLC lessened its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 47.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 104,483 shares of the biopharmaceutical company’s stock after selling 95,300 shares during the period. Bristol Myers Squibb accounts for approximately 1.1% of Hamilton Wealth LLC’s portfolio, making the stock its 23rd biggest position. Hamilton Wealth LLC’s holdings in Bristol Myers Squibb were worth $5,636,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb in the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. increased its holdings in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the last quarter. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $25,000. EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $32,000. Finally, Garner Asset Management Corp acquired a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $35,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.05% of the stock is currently owned by corporate insiders.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a quarterly dividend of $0.63 per share, reinforcing its income appeal with an annualized yield of about 4.6%. Bristol Myers Squibb Announces Dividend
• Positive Sentiment: The company reported positive Phase III SUCCESSOR-2 multiple myeloma data and additional encouraging pipeline results at the EHA 2026 conference, which could strengthen optimism around future oncology growth. Bristol Myers Squibb (BMY) Unveils Myeloma Trial Win And New Gulf Leadership
• Positive Sentiment: Independent coverage highlighted potential undervaluation in BMY, citing pipeline progress and margin improvement as reasons the stock may have upside from current levels. Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes
• Neutral Sentiment: Bristol Myers Squibb said it will report second-quarter 2026 results on July 30, keeping investors focused on the next earnings update. Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
• Neutral Sentiment: The company also appointed a new general manager for Saudi Arabia and Gulf countries, a strategic regional leadership move with limited near-term stock impact. Bristol Myers Squibb Appoints Mayada Al-Ahmad as General Manager for Saudi Arabia & Gulf Countries
• Negative Sentiment: Recent trading has been soft, with shares declining over the past month and quarter, and analysts still broadly rating the stock as a hold. Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

Analyst Ratings Changes

BMY has been the subject of several recent analyst reports. Wall Street Zen cut Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Cantor Fitzgerald upped their price target on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, April 8th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective on the stock. Finally, Barclays started coverage on shares of Bristol Myers Squibb in a research report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Stock Down 2.1%

Shares of NYSE BMY opened at $54.10 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The business’s 50 day moving average is $57.44 and its two-hundred day moving average is $57.11. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The firm has a market cap of $110.48 billion, a price-to-earnings ratio of 15.20, a PEG ratio of 0.16 and a beta of 0.24.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same period last year, the business posted $1.80 earnings per share. The company’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.7%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.